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Using clinical samples from patients with severe acute
respiratory syndrome, we showed that the sensitivities of a
quantitative reverse transcription–polymerase chain reac-
tion (80% for fecal samples and 25% for urine samples)
were higher than those of the polyclonal (50% and 5%) and
monoclonal (35% and 8%) antibody-based nucleocapsid
antigen capture enzyme-linked immunosorbent assays. 
T
he epidemic of severe acute respiratory syndrome
(SARS) in 2003, caused by SARS-associated coron-
avirus (SARS-CoV), has affected 30 countries, with 8,098
cases and 774 deaths (1–8). Early diagnosis of SARS-CoV
infection, which involves viral detection, is important for
preventing future epidemics. Since culturing of SARS-
CoV is difficult and insensitive, the reverse transcription–
polymerase chain reaction (RT-PCR) and quantitative RT-
PCR (qRT-PCR) has been the working standard in diagno-
sis (2,9). Nevertheless, these techniques are relatively
expensive and rely on the availability of equipment and
expertise. We recently reported the development of 2 sand-
wich enzyme-linked immunosorbent assays (ELISAs) for
detection of SARS-CoV nucleocapsid protein in clinical
specimens of SARS patients (10,11). However, no studies
have been conducted to compare the sensitivities of ELISA
with those of RT-PCR. Although PCR assays are generally
more sensitive, ELISAs are less expensive and easier to
conduct (12,13). To evaluate the potential usefulness of
ELISAin diagnosing SARS-CoV infections, we compared
the performance of ELISA and qRT-PCR and studied the
correlation between their results.
The Study
Fecal specimens (n = 40, from 40 patients 1–27 days
after symptom onset) and urine specimens (n = 133, from
101 patients 2–57 days after symptom onset) were collect-
ed from SARS patients hospitalized in Hong Kong from
March to May 2003. SARS was confirmed by the presence
of serum immunoglobulin (Ig) G against SARS-CoV by an
immunofluorescence assay (4). Specimens were tested
with polyclonal and monoclonal antibody–based capture
ELISAs for SARS-CoV nucleocapsid protein and real-
time qRT-PCR. Control urine (n = 100) and fecal (n = 100)
specimens were obtained from hospitalized patients with-
out SARS.
SARS-CoV nucleocapsid protein was detected by poly-
clonal antibody–based ELISA according to published pro-
tocols (7,11). SARS-CoV nucleocapsid protein was
detected by monoclonal antibody–based ELISA using a
modified protocol for serum samples (10). Briefly, fecal
and urine specimens were inactivated with 2% and 0.5%
phenol, respectively, for 15 min before centrifugation and
dilution in phosphate-buffered saline with 2% skim milk.
One hundred microliters of 1:10 diluted fecal specimens or
1:2 diluted urine specimens was added to wells previously
coated with antinucleocapsid monoclonal antibodies.
Plates were incubated, washed, treated with antinucleocap-
sid rabbit monoclonal antibodies, and analyzed as
described previously (10,11). RNA extraction and real-
time qPCR assay specific for the 1b region of SARS-CoV
were conducted as described previously (3,9). 
We compared the detection rates of 2 ELISAs and real-
time qRT-PCR using the McNemar test and studied the
correlation between the optical density values at 450 nm
(OD450) of the 2 ELISAs and log10 viral concentrations, as
determined by real-time qRT-PCR, by linear regression
(SPSS version 11.0, SPSS Inc., Chicago, IL, USA). A p
value <0.05 was regarded as significant.
A comparison of the 2 ELISAs is shown in the Figure
and Table 1. The cutoffs of the polyclonal antibody–based
ELISAhave been determined previously, with specificities
of 96% and 99% for fecal and urine specimens, respective-
ly (11). The baselines of the monoclonal antibody–based
ELISA were determined by using 100 control fecal and
urine specimens, with mean OD450 values of 0.089 and
0.05 and standard deviation (SD) values of 0.074 and 0.03,
respectively. The specificities of the monoclonal anti-
body–based ELISA were 93% for fecal specimens and
98% for urine specimens, as determined using cutoffs
defined as the mean + 2 SD. Of 40 fecal samples obtained
from SARS patients, 20 (50%) obtained on days 9 to 23
after onset of symptoms were positive by the polyclonal
antibody–based ELISA, and 14 (35%) obtained on days 2
to 21 were positive by the monoclonal antibody–based
ELISA. Of 133 urine samples, 6 (5%) obtained on days 16
to 32 after onset of symptoms were positive by the poly-
clonal antibody–based ELISA, and 11 (8%) obtained on
days 6 to 45 were positive by the monoclonal
antibody–based ELISA. Results of the polyclonal anti-
body–based ELISA were comparable with our previous
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Conclusions
The method of choice for early diagnosis of SARS-
CoV infection should be the qRT-PCR. The sensitivity of
qRT-PCR is superior to that of both ELISAs. Moreover,
qRT-PCR can detect SARS-CoV earlier in fecal specimens
(Tables 1 and 2). Among the 40 fecal samples from SARS
patients, 32 (80%) were positive by qRT-PCR, which was
significantly higher than that of the polyclonal (50%) and
monoclonal (35%) antibody-based ELISAs (McNemar
test, p<0.005 and p<0.001, respectively). Of the 133 urine
samples from SARS patients, 33 (25%) were positive by
qRT-PCR, which was also significantly higher than that of
the polyclonal (5%) and monoclonal (8%) antibody-based
ELISAs (McNemar test, p<0.001 for both comparisons).
When qRT-PCR was used as a standard, the sensitivities of
the polyclonal and monoclonal antibody–based ELISAs
were 53.1% (17/32) and 43.8% (14/32) in fecal specimens,
and 12.1% (4/33) and 15.2% (5/33) in urine specimens,
respectively. The qRT-PCR can detect SARS-CoV in fecal
specimens obtained on days 1 to 27 after onset of symp-
toms and in urine specimens obtained on days 9 to 45.
Moreover, 6 (75%) of the 8 fecal specimens obtained on
days 1 to 10 were positive by qRT-PCR. All 3 tests had the
highest detection rates in fecal specimens collected on
days 16 to 20, which suggested that this was the period of
peak viral shedding in stool. The detection rates in urine
specimens were much lower than those in fecal specimens
in all 3 assays. 
SARS-CoV can be detected during the late phase of ill-
ness. Since SARS-CoV cannot be readily isolated from
SARS patients after week 3 of illness (14), the detection of
SARS-CoV beyond this time may be due to prolonged
shedding of nonviable viruses in these patients or the pres-
ence of neutralizing immunoglobulins in clinical speci-
mens, which has prevented viral replication in cell
cultures. 
SARS-CoV RNA concentration and ELISA results
were correlated. Higher detection rates by both ELISAs
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Figure. Evaluation of polyclonal and monoclonal antibody-based
enzyme-linked immunosorbent assays (ELISAs) for detecting
nucleocapsid protein in fecal and urine specimens. The dashed
horizontal lines represent the corresponding cutoff optical density
values at 450 nm (OD450). SARS, severe acute respiratory syn-
drome.were found in specimens with higher viral concentrations
(Table 2). There was also a significant correlation between
viral load and ELISAOD450 values in fecal specimens test-
ed with the monoclonal antibody–based ELISA (Pearson
correlation 0.424, p = 0.003), and in urine specimens test-
ed with both the polyclonal and monoclonal
antibody–based ELISAs (Pearson correlation 0.386 and
0.331, respectively, p<0.0005 in both analysis). Although
the correlation between viral load and ELISAOD450 values
in fecal specimens tested with the polyclonal
antibody–based ELISA was not significant, there was a
trend for such a correlation (Pearson correlation 0.229, p =
0.078).
In this study, fecal and urine samples were used because
they are easier and safer to obtain and more readily avail-
able. In our previous reports, nucleocapsid protein was
detected by the polyclonal antibody–based ELISA in 83%
of nasopharyngeal aspirates collected on days 11 to 15
after symptom onset and by the monoclonal
antibody–based ELISA in 85% of serum obtained during
the first 10 days (10,11). These findings suggest that
ELISA may be more useful when used with nasopharyn-
geal aspirate and serum specimens. However, these speci-
mens were not included in the current study because only
small amounts were available. Similar studies should be
conducted if such samples are available.
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